Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 2006 Mar;81(3):193-8
Date
02/24/2006Pubmed ID
16493620DOI
10.1002/ajh.20516Scopus ID
2-s2.0-33644550950 (requires institutional sign-in at Scopus site) 94 CitationsAbstract
Thrombocytopenia developing in the course of chemotherapy for malignant disease is usually attributed to drug-induced marrow suppression and/or marrow replacement by tumor. We describe two patients who developed severe thrombocytopenia and hemorrhagic symptoms while being treated with oxaliplatin, 5-fluorouracil, and leukovorin for metastatic colon cancer in whom platelet destruction appears to have been caused by oxaliplatin-dependent antibodies specific for the platelet glycoprotein IIb/IIIa complex (alpha(IIb)/beta(3) integrin). Drug-induced immune thrombocytopenia (DITP) should be considered in patients who experience a sudden, isolated drop in platelet levels while being treated with chemotherapeutic agents, especially when adequate numbers of megakaryocytes are present in the bone marrow.
Author List
Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RHAuthor
Brian Curtis PhD Director in the Platelet & Neutrophil Immunology Laboratory department at BloodCenter of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAntineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Autoantibodies
Bone Marrow Cells
Carcinoma
Colonic Neoplasms
Female
Fluorouracil
Humans
Leucovorin
Megakaryocytes
Middle Aged
Neoplasm Metastasis
Organoplatinum Compounds
Purpura, Thrombocytopenic, Idiopathic
Vitamin B Complex
